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ORIGINAL ARTICLESerum Polyclonal Immunoglobulin Free Light
Chain Levels Predict Mortality in People With
Chronic Kidney Disease
Colin A. Hutchison, PhD; Anne Burmeister, PhD; Stephen J. Harding, PhD;
Kolitha Basnayake, PhD; Hannah Church, MBChB; Mark D. Jesky, MBChB;
Katie White, MBChB; Clara E. Green, MBChB; Stephanie J. Stringer, PhD;
Paul Bassett, MSc; Charles J. Ferro, MD; and Paul Cockwell, PhDAbstract
Objective: To determine whether elevated serum polyclonal free light chain (FLC) levels predict mortality
in a population of individuals with chronic kidney disease (CKD).
Patients and Methods: From January 2, 2006, through July 31, 2007, we recruited a cohort of 848 people
with CKD who were not receiving renal replacement therapy and did not have monoclonal gammopathy.
We measured serum kappa FLC and lambda FLC isotype levels to determine combined FLC (cFLC) levels.
The cohort was prospectively followed up for a median of 63 months (interquartile range, 0-93 months).
Cox regression analysis was performed to determine variables predictive of mortality.
Results: High cFLC levels were an independent risk factor for death (hazard ratio [HR], 2.71; 95%CI, 1.98-
3.70; P<.001). Other independent risk factors were age (HR, 1.79; 95% CI, 1.52-2.10; P<.001), South
Asian ethnicity (HR, 0.33; 95% CI, 0.14-0.64; P¼.02), preexisting cardiovascular disease (HR, 1.59; 95%
CI, 1.09-2.31; P¼.02), and high-sensitivity C-reactive protein (HR, 1.13; 95% CI, 1.00-1.28; P¼.04).
Neither estimated glomerular ﬁltration rate nor albuminuria was an independent risk factor for death.
Conclusion: High cFLC levels independently predict mortality in people with CKD.
ª 2014 Mayo Foundation for Medical Education and Research.
n Mayo Clin Proc. 2014;89(5):615-622
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(P.B.).C hronic kidney disease (CKD) affectsmore than 10% of the adult popula-tion,1,2 and a high proportion of total
health care budgets is used in managing pa-
tients with CKD.3,4 The mortality associated
with CKD is high and is related to both base-
line kidney function and the rate of progres-
sion of CKD.5,6 The major cause of increased
mortality is cardiovascular disease (CVD),
although there is also increased mortality
from cancer and infections.7,8
To better target management in CKD,
enhanced risk stratiﬁcation is required.1 At
present, risk assessment is based on the mea-
surements of kidney function (estimated
glomerular ﬁltration rate [eGFR]) and kidney
injury (proteinuria). However, as chronic
inﬂammation is an important component of
risk in CKD,9 the serum levels of molecules
that are affected by both kidney function and
immune/inﬂammatory status may representMayo Clin Proc. n May 2014;89(5):615-622 n http://dx.doi.org/10.10
www.mayoclinicproceedings.org n ª 2014 Mayo Foundation for Mbetter tools for risk assessment than do current
routine tests.
Immunoglobulin light chains are a compo-
nent of the intact immunoglobulin molecule
produced by plasma cells and other cells of the
B-cell lineage. Free light chains (FLCs) are
produced in excess during immunoglobulin
synthesis and are cleared from the serum by
the kidneys; therefore, a decrease in the GFR is
associated with an increase in serum FLC levels.
An assessment of the ratio of the 2 isotypes of
FLCdkFLC and lFLCdis widely used in the
diagnosis and management of plasma cell disor-
ders to identify and quantify monoclonal
FLC.10,11 However, the measurement of serum
polyclonal FLCmay also identify global immune
activation. Recent studies have found an associ-
ation between increased levels of polyclonal FLC
and outcomes in the general population and in
people with autoimmune disease, cancer, and
kidney disease.12-1816/j.mayocp.2014.01.028
edical Education and Research.
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616Therefore, the objective of this study was
to evaluate the hypothesis that serum levels
of polyclonal FLC are predictive of mortality
in people with CKD. To address this, we per-
formed a large cohort study of people with
CKD (nonerenal replacement therapy) incor-
porating other bioclinical variables of known
importance for outcomes.
PATIENTS AND METHODS
The study was approved by the Solihull and
South Birmingham Research Ethics commit-
tees (reference number 05/Q2702/50) and
the R&D department of University Hospitals
Birmingham NHS Foundation Trust. All pa-
tients gave informed written consent to partic-
ipate in the study.
Study Population
From January 2, 2006, through July 31, 2007,
we recruited a cohort (n¼916) of patients un-
der follow-up in adult kidney disease clinics at
University Hospitals Birmingham. Patients
were approached on the basis of the following
selection criteria: they fulﬁlled the K/DOQI
criteria for CKD,19 and they were not receiving
renal replacement therapy (through dialysis or
a functioning kidney transplant). All patients
who fulﬁlled these criteria and who had an
appointment in a clinic attended by the
enrolling investigator (C.A.H.) were provided
with written information about the study and
then approached and asked to provide
informed consent for the study. Once the pa-
tients were enrolled in the study, the following
baseline parameters were collected: age, sex,
ethnicity, CVD comorbidity (ischemic heart
disease, cardiac failure, cerebrovascular dis-
ease, and peripheral vascular disease), diabetes
mellitus, blood pressure (BP), medications,
urinary albumin/creatinine ratio (ACR), and
serum laboratory variables (albumin, phos-
phate, calcium, creatinine, cystatin C,
high-sensitivity C-reactive protein (hsCRP),
estimated glomerular ﬁltration rate (eGFR)
by the abbreviated modiﬁcation of diet in renal
disease equation (MDRD), and serum FLC.
Sixty-eight patients (7.4%) were excluded
from the analysis because they had a mono-
clonal gammopathy of undetermined signiﬁ-
cance (MGUS) at the time of recruitment. A
diagnosis of MGUS is independently associ-
ated with an increased mortality20,21 andMayo Clin Proc. n May 2014abnormalities in FLC independent of kidney
function.22 Therefore, 848 patients (92.6%)
were included in this analysis.
Laboratory Analysis
Creatinine, albumin, calcium, and phosphate
were measured using a Roche Modular Analyser
(Roche Diagnostics); the normal ranges were as
follows: 50 to 125 mmol/L, 35 to 50 g/L, 2.25
to 2.75 mmol/L, and 0.8 to 1.4 mmol/L, respec-
tively. Urine albumin and creatinine were
measured by using automated immunotur-
bidimetry with antibody against human albu-
min and a compensated version of the Jaffe
reaction (Roche Diagnostics). A normal ACR
was deﬁned as less than 2.5 mg/mmol for men
and less than 3.5 mg/mmol for women. The re-
sults reported for ACR, systolic BP, and diastolic
BP are the median of 3 clinic appointments: the
recruitment clinic, the clinic before recruitment,
and the clinic after recruitment.
To diagnose a MGUS, sera were tested by
serum protein electrophoresis (Sebia Hydragel
Protein kit on the Hydrasys system, Sebia) and
serum FLC immunoassays (Freelite on the
Dade-Behring BN II Analyser, The Binding Site
Group Ltd). If either test gave abnormal results,
serum immunoﬁxation electrophoresis was
used (Sebia Hydragel Immunoﬁxation PE kit
on the Hydrasys system). The presence of a
monoclonal protein indicative of a MGUS was
deﬁned by an intact immunoglobulin band us-
ing immunoﬁxation electrophoresis or an
abnormal serum FLC ratio with a corresponding
elevation in the concentration of involved FLC
isotype (FLC-MGUS). The reference range for
the serum FLC ratio in renal disease is 0.37 to
3.1.23,24 Polyclonal FLC concentrations were
determined by combining serum kFLC and
lFLC concentrations (combined FLC [cFLC]);
the reference range was 9.3 to 43.3 mg/L.17
Statistical Analyses
Excluding patients who died, the cohort was pro-
spectively followed up for amedian of 68months
(interquartile range [IQR], 52-93 months). The
cause of death was that recorded on the death
certiﬁcate held by the General Register Ofﬁce.
The causes of death were categorized as CVD,
infection, cancer, renal failure, or other.
The Kaplan-Meier method was used to
analyze quintiles of cFLC levels. Cox propor-
tional hazards regression analysis was used to;89(5):615-622 n http://dx.doi.org/10.1016/j.mayocp.2014.01.028
www.mayoclinicproceedings.org
TABLE 1. Population Demographic and Baseline Characteristics of 848 Patients
With CKDa,b
Age (y) 6017
Sex: male 54
Ethnicity
White 79
South Asian 11
African Caribbean 7
Other 3
ACR (mg/mmol) 10 (2-59)
Albumin (g/L) 434.42
Calcium (mmol/L) 2.290.15
Phosphate (mmol/L) 1.300.28
Creatinine (mmol/L) 153 (112-222)
eGFR (mL/min per 1.73 m2) 4527.63
kFLC (mg/L) 27 (16-47)
lFLC (mg/L) 28 (18-44)
cFLC (mg/L) 56 (35-91)
Renal disease
Glomerulonephritis 39
Pyelonephritis/renal tract calculi 7
Interstitial nephritis 3
Hereditary nephropathies 8
Hypertensive/renovascular 23
Diabetic nephropathy 8
Other 14
aACR ¼ albumin creatinine ratio; cFLC ¼ combined free light chain; CKD ¼ chronic kidney
disease; eGFR ¼ estimated glomerular ﬁltration rate; kFLC ¼ kappa free light chain; lFLC ¼
lambda free light chain.
bValues are presented as mean  SD, No. (percentage), or median (interquartile range).
POLYCLONAL FREE LIGHT CHAINS PREDICT MORTALITY IN CKDexamine factors associated with survival times.
Those alive at the end of the study period were
censored according to their follow-up time. In
addition, logistic regressionwas used to examine
factors associated with 1-year survival.
Univariate analyses were performed to the
end of the study period and for 1-year survival
in relation to the variables collected at base-
line. These comprised age, sex, ethnicity,
CVD comorbidity (ischemic heart disease, car-
diac failure, cerebrovascular disease, and pe-
ripheral vascular disease), BP, and the use of
angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers, and serum lab-
oratory variables (albumin, phosphate, cal-
cium, creatinine, cystatin C, hsCRP, eGFR,
and serum FLC). Continuous variables with
a highly skewed distribution were log trans-
formed before analysis. Indicator variables
were used to ﬁt categorical predictor variables.
Those variables with P<0.2 in a univariate
analysis were included in a multivariate analysis.
For overall survival, this analysis comprised all
independent variables. For CVD, the variable
any CVD (not individual diseases) was included
to represent one or more CVD comorbidities.
For survival at 1 year, ethnicity, diastolic BP,
and ACR had a P.2 and were not included in
the multivariate analysis. Before the multivariate
analysis, the colinearity between the variables
was determined; variance inﬂation factors with
a value above 10 were considered as evidence
of colinearity. The variables serum creatinine
and the abbreviated modiﬁcation of diet in renal
disease estimated glomerular ﬁltration rate
(MDRD eGFR) were colinear, and eGFR was
included in the multivariate analysis. kFLC,
lFLC, and cFLC were also colinear; cFLC was
included in the multivariate analysis. A back-
ward selection procedure was used to retain var-
iables that were statistically signiﬁcant by using a
signiﬁcance level of .05.
Continuous variables were compared be-
tween groups using the analysis of variance
and the Kruskal-Wallis test, as appropriate. An-
alyses using receiver operating characteristic
curves examined the utility of routine laboratory
tests for kidney function and serum cFLC for the
prediction of death at 1 year. The area-under-
the-curve (AUC) values for each variable with
the corresponding CI were calculated.
In addition, analyses examined factors
associated with individual causes of death.Mayo Clin Proc. n May 2014;89(5):615-622 n http://dx.doi.org/10.10
www.mayoclinicproceedings.orgCox proportional hazards regression models
were again used for the analysis. Patients who
did not die were censored at the time of last
follow-up, whereas those who died of a
different cause were censored at the time of
death.
Analysis was performed using SPSS (version
21, IBM Corporation) and Stata Statistical Soft-
ware (version 12.1, Stata Corporation).
RESULTS
Demographic characteristics, laboratory data, and
renal diagnoses are given in Table 1. The cohort
was predominately white (79% of stated; 656),
with a mean age of 60 years; 54% (455) were
men. Twenty-one percent of the patients had dia-
betes as a comorbidity. The patients were distrib-
uted according to theCKDstage: stage 1, 2% (17);
stage 2, 17% (142); stage 3a, 19% (158); stage 3b,
27% (229); stage 4, 25% (212); stage 5, 8% (70)
and not stated 2% (20). The median duration of
follow-up for thewhole cohort (including deaths)
was 63 months (IQR range, 0-93 months),16/j.mayocp.2014.01.028 617
TABLE 2. Cox Regression Analysis of Variables
Associated With All-Cause Mortality: Univariate
Analysisa,b
Variable
Hazard ratio
(95% CI) P value
Age (y)c 2.20 (1.90-2.53) <.001
Sex
Male 1.76 (1.28-2.43) .001
Female 1
Ethnicity
White 1 .05
South Asian 0.42 (0.22-0.83)
African Caribbean 0.72 (0.37-1.41)
Other 0.55 (0.17-1.71)
CKD stage
1-2 1 <.001
3a 1.00 (0.38-2.70)
3b 4.53 (2.14-9.56)
4 7.37 (3.55-15.30)
5 9.97 (4.55-21.80)
ACE inhibitors
No 1 .05
Yes 0.73 (0.53-1.00)
IHD
No 1 <.001
Yes 2.60 (1.81-3.74)
MI/angioplasty
No 1 .01
Yes 1.94 (1.17-3.20)
PVD
No 1 <.001
Yes 3.08 (1.95-4.88)
CVA
No 1 <.001
Yes 2.90 (1.73-4.86)
Cardiovascular disease
(any)
No 1 <.001
Yes 3.54 (2.58-4.85)
Diabetes
No 1 <.001
Yes 1.98 (1.43-2.73)
Systolic BP (mm Hg)c 1.15 (1.07-1.23) <.001
Diastolic BP (mm Hg)c 0.79 (0.68-0.92) .002
ACR (mg/mmol)d 1.12 (1.03-1.22) .01
Albumin (g/L)e 0.85 (0.74-0.97) .02
Calcium (mmol/L) 0.21 (0.09-0.51) .001
Phosphate (mmol/L) 3.72 (2.24-6.19) <.001
Creatinine (mmol/L)d 3.58 (2.72-4.72) <.001
MDRD eGFR (mL/min
per 1.73 m2) 0.64 (0.58-0.71) <.001
hsCRP (mg/L)d 1.44 (1.27-1.62) <.001
Cystatin C (mg/L) 1.69 (1.53-1.87) <.001
cFLC (mg/L)d 3.21 (2.56-4.02) <.001
kFLC (mg/L)d 3.06 (2.40-3.80) <.001
lFLC (mg/L)d 3.00 (2.40-3.76) <.001
Continued
TABLE 2. Continued
Variable
Hazard ratio
(95% CI) P value
Renal disease
Glomerulonephritis 1 <.001
Pyelonephritis/renal
tract calculi 1.81 (0.85-3.81)
Interstitial nephritis 2.55 (0.99-6.60)
Hereditary
nephropathies 1.23 (0.54-2.82)
Hypertensive/
renovascular 4.29 (2.76-6.66)
Diabetic nephropathy 4.35 (2.48-7.63)
Other 3.47 (2.11-5.72)
aACE ¼ angiotensin-converting enzyme; ACR ¼ albumin
creatinine ratio; BP ¼ blood pressure; cFLC ¼ combined free
light chain; CKD ¼ chronic kidney disease; CVA ¼ cerebro-
vascular accident; eGFR ¼ estimated glomerular ﬁltration rate;
hsCRP ¼ high-sensitivity C reactive protein; IHD ¼ ischemic
heart disease; kFLC ¼ kappa free light chain; lFLC ¼ lambda
free light chain; MDRD ¼ modiﬁcation of diet in renal disease;
MI ¼ myocardial infarction; PVD ¼ peripheral vascular disease.
bACR, systolic BP, and diastolic BP values presented are the
median of 3 clinic appointments.
cAnalyzed in 10-unit increases.
dAnalyzed on a log scale.
eAnalyzed in 5-unit increases.
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618 Mayo Clin Proc. n May 2014whereas themedian duration for the patientswho
did not die was 68 months (IQR range, 52-93
months). In total, there were 50,675 patient-
months available for analysis. At the end of
follow-up, 20% (167) of the patients had died.Serum FLC Levels and Survival
The median serum polyclonal FLC levels were
as follows: kFLC, 27 mg/L (IQR, 16-47 mg/L);
lFLC, 28 mg/L (IQR, 18-44 mg/L); cFLC, 56
mg/L (IQR, 35-91 mg/L) (Table 1). The cFLC
levels were inversely related to eGFRs (Kruskal-
Wallis test, P<.001). Univariate Cox regression
analysis indicated that a number of demo-
graphic, clinical, and laboratory variables were
associated with survival (Table 2). Higher levels
of serum FLC, both as single isotypes and as
cFLC, were associated with reduced survival; a
1-unit increase in cFLC (on the log scale) was
associated with a 3-fold increased risk of death
(hazard ratio [HR], 3.21; 95% CI, 2.56-4.02).
This ﬁnding was true for both kFLC (HR, 3.06;
95% CI, 2.40-3.80) and lFLC (HR, 3.00; 95%
CI, 2.40-3.76) isotypes (Table 2). A Kaplan-
Meier survival plot for the cohort by quintiles
of cFLC levels is shown in the Figure.;89(5):615-622 n http://dx.doi.org/10.1016/j.mayocp.2014.01.028
www.mayoclinicproceedings.org
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FIGURE. Survival by quintiles of combined FLC levels. Higher combined
FLC levels were associated with a signiﬁcantly reduced survival (P<.001).
POLYCLONAL FREE LIGHT CHAINS PREDICT MORTALITY IN CKDBecause there was marked colinearity
between the level of the 2 FLC isotypes and
cFLC level, only cFLC was included in the
multivariate analysis. Similarly, creatinine was
excluded from the multivariate analysis and
eGFR retained. Multivariate analysis indicated
that cFLC, age, ethnicity, cardiovascular co-
morbidity, and hsCRP were all independently
associated with mortality (Table 3). Of these
variables, cFLC had the highest HR for death
(HR, 2.71; 95% CI, 1.98-3.70). All other vari-
ables, including eGFR and ACR, were not inde-
pendent signiﬁcant predictors of mortality.
Importantly, cFLC remained signiﬁcantly
associated when deaths within the ﬁrst year of
follow-up were analyzed (odds ratio [OR],
3.70 for a 1-unit increase on the log scale;
95% CI, 2.14-6.41; P<.001). The multivariate
analysis of signiﬁcant variables found age (OR,
1.75 for a 10-year increase; 95% CI, 1.19-
2.56; P¼.005), CVD (OR, 3.14; 95% CI, 1.34-
7.37; P¼.008), cFLC (OR, 2.20; 95% CI,
1.03-4.75; P¼.04), and hsCRP (OR, 1.50;
95% CI, 1.10-2.02; P¼.009) to be indepen-
dently predictive of mortality within 1 year.
Furthermore, the AUC statistic was greater for
the prediction of survival when using this com-
bination of variables (AUC statistic, 0.86)
compared with any of the classically measured
renal markers (Table 4).
Causes of Death
The causes of death were identiﬁed in 164 of 167
patients who died. The major causes of death
(where reported) were CVD (39%), infections
(27%), cancers (18%), and renal failure (11%).
Eight percent of the patients died of other causes.
The proportion of individuals who died progres-
sively increased with higher FLC quintiles (3.7%,
10.9%, 14.1%, 24.1%, and 43.8%); however, the
distribution of causes of death was not signiﬁ-
cantly different between the FLC quintiles: CVD
(50.0%, 21.1%, 33.3%, 41.5%, and 43.2%),
infection (16.7%, 31.6%, 33.3%, 31.7%, and
23.0%), and cancer (16.7%, 36.8%, 16.7%,
4.9%, and 20.3%) (c2 test, P¼.245). Univariate
Cox regression analysis found a signiﬁcant associ-
ation between cFLC and each cause of death
(CVD HR, 3.65; infection HR, 3.00; renal HR,
3.91; cancer HR, 2.53, all P<.001 for a 1-unit in-
crease on the log scale). Multivariate analysis
found that cFLC independently predicted deaths
fromCVD (HR, 2.97;P<.001), cancer (HR, 2.06;Mayo Clin Proc. n May 2014;89(5):615-622 n http://dx.doi.org/10.10
www.mayoclinicproceedings.orgP¼.02), and infection (HR, 1.84;P¼.03); in addi-
tion, age was an independent risk factor for death
from all 4 causes (CVD HR, 1.68, P<.001; infec-
tion HR, 2.11, P<.001; renal HR, 2.85, P<.001;
cancer HR, 1.76, P¼.001 for a 10-year increase
on the log scale); history of CVD was associated
with cardiovascular mortality (HR, 2.08;
P¼.005); hsCRP (HR, 1.32; P¼.02) and male
sex (HR, 2.70; P¼.02) were independently asso-
ciated with deaths from infection; cystatin C (HR
1.70; P¼.04) and systolic BP (HR 1.30; P¼.02)
were predictive of renal mortality.DISCUSSION
The objective of this study was to determine
whether serum levels of polyclonal immuno-
globulin cFLC can stratify people with CKD
for the risk of mortality. In this cohort of 848
individuals with CKD, cFLC predicted mortal-
ity independently of all other factors studied,
including kidney function and hsCRP.
Increasing serum levels of both kFLC and
lFLC and the summation of the 2 isotypes
(cFLC) predicted increased mortality. As antic-
ipated, the colinearity between these 3 variables16/j.mayocp.2014.01.028 619
TABLE 3. Cox Regression Analysis of Variables Associated With All-Cause
Mortality: Multivariate Analysisa
Variable
Hazard ratio
(95% CI) P value
Age (y)b 1.79 (1.52-2.10) <.001
Ethnicity
White 1
South Asian 0.33 (0.14-0.64)
African Caribbean 0.72 (0.32-1.67) .02
Other 0.73 (0.24-2.42)
Cardiovascular disease (any)
No 1
Yes 1.59 (1.09-2.31) .02
cFLC (mg/L)c 2.71 (1.98-3.70) <.001
hsCRP (mg/L)c 1.13 (1.00-1.28) .04
acFLC ¼ combined free light chain; hsCRP ¼ high-sensitivity C reactive protein.
bAnalyzed in 10-unit increases.
cAnalyzed on a log scale.
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620was high; therefore, in the multivariate analysis,
only cFLC was evaluated.
To date, this is the largest study on associ-
ations between polyclonal FLC and clinical out-
comes in patients with CKD. In a recent study
on associations between monoclonal and poly-
clonal FLC in patients with CKD, we found an
overall association between lFLC and survival
in a multivariable analysis of a range of clinical
variables, including markers of cardiac injury
(N-terminal prohormone of brain natriuretic
peptide and troponin). The cohort was smaller,
had advanced CKD (median eGFR, 21.9 mL/
min per 1.73 m2), and had high comorbidity
as compared with those measured in the pre-
sent study.16TABLE 4. AUC Analysis of Variables Associated
With Renal Function or Signiﬁcant by Multivariate
Analysis and Survival at 1 ya
Variable
AUC
(95% CI)
MDRD eGFR 0.67 (0.60-0.75)
ACR 0.54 (0.45-0.63)
Cystatin C 0.74 (0.67-0.82)
cFLC 0.74 (0.67-0.82)
Multivariate regression modelb 0.86 (0.79-0.93)
aAUC ¼ area under the curve; ACR ¼ albumin creatinine
ratio; cFLC ¼ combined free light chain; eGFR ¼ estimated
glomerular ﬁltration rate; MDRD ¼ modiﬁcation of diet in
renal disease.
bMultivariate regression model consisting of age, cardiovascular
disease, FLC, and hsCRP.
Mayo Clin Proc. n May 2014In the general population, there are 2 large
cohorts with data available on the association
between polyclonal FLC and outcomes.
First, Dispenzieri et al17 analyzed outcomes
in approximately 16,000 people included in
the Olmsted county cohort and found, by us-
ing multivariable analysis, an independent
mortality risk associated with high polyclonal
cFLC levels. Second, the German Heinz Nix-
dorf Recall health-screening study found an
independent association between polyclonal
FLC and survival in 4350 people.25 In addition,
a recent study has used data from patients who
have undergone routine hematological assess-
ments for a monoclonal gammopathy; in patients
with a monoclonal gammopathy excluded,
elevated cFLC levels were independently associ-
ated with increased mortality.12
Serum levels of cFLC are representative of
2 factors: (1) their production rates and (2)
their serum half-lives. The basic immunoglob-
ulin molecule consists of 2 heavy chains and 2
light chains that are linked by disulﬁde bonds.
The production of FLC is related to an excess
production of light chains over heavy chains,
such that excess FLCs are released into the cir-
culation in health at an estimated rate of 500
mg/d. Although any cell derived from the B-
cell lineage can produce FLC, most of the
FLCs will be released from mature plasma
cells. The production rate of FLC therefore
represents the activity of the adaptive immune
system.
The second effect on the serum levels of
FLC is serum half-life, which is predominantly
affected by kidney function.23 Both isotypes of
FLC are molecules that are cleared by glomer-
ular ﬁltration, and so as kidney function levels
(GFR) decrease, serum FLC levels increase.
There was a close association between the
absolute serum FLC levels and kidney function,
and so cFLC levels increased with the
decreasing levels of kidney function. Serum
cFLC levels were predictive of overall survival
in both univariate and multivariate analyses.
A further evaluation of the cause of death estab-
lished that cFLC levels were independently
associated with deaths fromCVD and infection.
Moreover, the risk associated with cFLC was
independent of eGFR and ACR.
The association described herein between
serum levels of cFLC and mortality identiﬁes
FLC as a biomarker of potential clinical utility.;89(5):615-622 n http://dx.doi.org/10.1016/j.mayocp.2014.01.028
www.mayoclinicproceedings.org
POLYCLONAL FREE LIGHT CHAINS PREDICT MORTALITY IN CKDHowever, FLC could also be mechanistically
involved in the poor outcomes of this popula-
tion, although the data for this are currently
sparse. Although the pathways by which mono-
clonal FLC cause direct tissue injury in diseases
such as multiple myeloma and amyloid light
chain amyloidosis are well described,26,27 there
is less evidence to date for polyclonal FLC,
with studies limited to in vitro experiments
establishing a role of polyclonal FLC in the inhi-
bition of leukocyte phagocytosis and in chronic
inﬂammation.28
CONCLUSION
This study reports a potential role of poly-
clonal cFLC to act as a biomarker by which
patients with CKD can be risk stratiﬁed for
mortality. The principal limitation of the study
is the cross-sectional design and short follow-
up. Further studies are required to identify
how the association between serum FLC levels
and mortality can be used to improve out-
comes for people with CKD and the mecha-
nistic basis for this association.Abbreviations and Acronyms: ACR = albumin creatinine
ratio; AUC = area under the curve; BP = blood pressure;
cFLC = combined free light chain; CKD = chronic kidney
disease; CVD = cardiovascular disease; eGFR = estimated
glomerular ﬁltration rate; FLC = free light chain; hsCRP =
high-sensitivity C-reactive protein; HR = hazard ratio;
IQR = interquartile range; kFLC = kappa free light chain;
lFLC = lambda free light chain; MGUS = monoclonal
gammopathy of undetermined signiﬁcance
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